Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Functional imaging methods such as fMRI have been widely used to gain greater understanding of brain circuitry abnormalities in CNS disorders and their underlying neurochemical basis. Findings suggest that: (1) drugs with known clinical efficacy have consistent effects on disease relevant brain circuitry, (2) brain activation changes at baseline or early drug effects on brain activity can predict long-term efficacy; and (3) fMRI together with pharmacological challenges could serve as experimental models of disease phenotypes and be used for screening novel drugs. Together, these observations suggest that drug related modulation of disease relevant brain circuitry may serve as a promising biomarker/method for use in drug discovery to demonstrate target engagement, differential efficacy, dose-response relationships, and prediction of clinically relevant changes.

Original publication

DOI

10.1016/j.coph.2013.11.009

Type

Journal article

Journal

Curr Opin Pharmacol

Publication Date

02/2014

Volume

14

Pages

54 - 61

Keywords

Animals, Biomarkers, Brain, Central Nervous System Diseases, Drug Design, Drug Discovery, Functional Neuroimaging, Humans, Magnetic Resonance Imaging, Mental Disorders